Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CARDIOVASCULAR > Arrhythmias > Flashcards

Arrhythmias Flashcards

1
Q

What key considerations should be had in the ABCDE approach to a tachycardia with pulse

A
  1. Give oxygen if SpO2 < 94%
  2. Obtain IV access
  3. Monitor ECG, BP, SpO2, record 12-lead ECG
  4. Identify and treat reversible causes e.g. electrolyte abnormalities, hypovolaemia causing sinus tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What life-threatening features should you be aware of when managing tachycardia?

A
  1. Shock
  2. Syncope
  3. Myocardial ischaemia
  4. Severe heart failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

In the presence of life threatening features, how would you manage tachycardia?

A

Synchronised DC shock up to 3 attempts (sedation or anaesthesia if conscious)

If unsuccessful:
* Amiodarone 300 mg IV over 10–20 min
* Repeat synchronised DC shock

(in 2015 resus flowchart, next step is 900mg IV amiodarone over 24hr, but this is not present in 2021 resus flowchart)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In the absence of life-threatening features, what ECG feature is used to group tachycardias

A

QRS duration.
* >0.12s (3 small squares) –> broad complex tachycardia
* <0.12s (“) –> narrow complex tachycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Broad complex tachycardia with irregular rhythm

A

Atrial fibrillation with bundle branch block
- treat as for irregular narrow complex

Polymorphic VT (e.g. torsades de pointes)
- give magnesium 2g over 10 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Broad complex tachycardia with regular rhythm

A

If VT (or uncertain rhythm):
* Amiodarone 300 mg IV over 10–60 min

If previous certain diagnosis of SVT with bundle branch block/ aberrant conduction:
* Treat as for regular narrow complex tachycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Narrow complex tachycardia with irregular rhythm

A

Probable atrial fibrillation:
* Control rate with beta-blocker
* Consider digoxin or amiodarone if evidence of heart failure
* Anticoagulate if duration > 48 h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Narrow complex tachycardia with regular rhythm

A
  1. Vagal manoeuvres
  2. If ineffective:
    * Give Adenosine (if no pre-excitation)
    – 6 mg rapid IV bolus
    – If unsuccessful, give 12 mg
    – If unsuccessful, give 18 mg
    * Monitor ECG continuously
  3. If ineffective:
    * Verapamil or beta-blocker
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

If initial treatment is ineffective for regular tachycardias (both broad and narrow), what can you do next?

A

If ineffective:
* Synchronised DC shock up to 3 attempts
* Sedation or anaesthesia if conscious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What conditions are supraventricular tachycardias (SVTs)

A
  • Atrial flutter/tachycardia
  • Atrio-ventricular nodal re-entry tachycardia (AVNRT)
  • Atrio-ventricular re-entrant tachycardia (AVRT)
  • Atrial fibrillation (irregular, but also generated SVT)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Atrial flutter

A
  • Substrate originates from atrial chambers (focal or re-entrant)
  • Saw-tooth appearance
  • Counter-clockwise circuit going through the atria
  • Treatment: ablation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

AFib: types

A

either first detected episode, paroxysmal, persistent or permanent

  1. first detected episode (irrespective of whether it is symptomatic or self-terminating)
  2. recurrent episodes, when a patient has 2 or more episodes of AF.
    - If episodes of AF terminate spontaneously then the term paroxysmal AF is used. Such episodes last less than 7 days (typically < 24 hours).
    - If the arrhythmia is not self-terminating then the term persistent AF is used. Such episodes usually last greater than 7 days
  3. in permanent AF there is continuous atrial fibrillation which cannot be cardioverted or if attempts to do so are deemed inappropriate. Treatment goals are therefore rated control and anticoagulation if appropriate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Afib: signs and symptoms

A

Symptoms
- palpitations
- dyspnoea
- chest pain

Signs
- an irregularly irregular pulse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Afib: investigations

A

ECG is essential to make the diagnosis as other conditions can give an irregular pulse, such as ventricular ectopics or sinus arrhythmia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Afib: key management aspects

A

There are two key parts of managing patients with AF:
1. Rate/rhythm control
2. Reducing stroke risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the difference between rate and rhythm control

A

rate control: accept that the pulse will be irregular, but slow the rate down to avoid negative effects on cardiac function

rhythm control: try to get the patient back into, and maintain, normal sinus rhythm. This is termed cardioversion. Drugs (pharmacological cardioversion) and synchronised DC electrical shocks (electrical cardioversion) may be used for this purpose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Situations where rhythm control considered over rate

A

coexistent heart failure, first onset AF or where there is an obvious reversible cause.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Drugs used in rate control

A

First-line: beta-blocker or a rate-limiting calcium channel blocker (e.g. diltiazem)

If one drug does not control the rate adequately NICE recommend combination therapy with any 2 of the following:
a betablocker
diltiazem
digoxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Risk of cardioversion - stroke
1. Important safety measure

A

The moment a patient switches from AF to sinus rhythm presents the highest risk for embolism leading to stroke. Imagine the thrombus formed in the fibrillating atrium suddenly being pushed out when sinus rhythm is restored.
1. short duration of symptoms (less than 48 hours) or be anticoagulated for a period of time prior to attempting cardioversion.

20
Q

CHA2DS2-VASc
1. Treatment suggestion based on score

A
  • determine the most appropriate anticoagulation strategy

C Congestive heart failure 1
H Hypertension (or treated hypertension) 1
A2 Age >= 75 years 2
Age 65-74 years 1
D Diabetes 1
S2 Prior Stroke, TIA or thromboembolism 2
V Vascular disease (including ischaemic heart disease and peripheral arterial disease) 1
S Sex (female) 1

0 No treatment
1 Males: Consider anticoagulation
Females: No treatment (this is because their score of 1 is only reached due to their gender)
2 or more Offer anticoagulation

If CHADVASc = 0, TTE to exclude valvular disease (+Afib = absolute indication for anticoag)

21
Q

AFib: anticoagulation

A

1st line: DOAC (apixaban, dabigatran, edoxaban, rivaroxaban)
2nd line: warfarin

DOAC>warfarin = no regular INR checks

NO ASPIRIN

22
Q

Rate vs rhythm control in Af (haemodynamically stable patients)

A

< 48 hours: rate or rhythm control
≥ 48 hours or uncertain (e.g. patient not sure when symptoms started): rate control
if considered for long‑term rhythm control, delay cardioversion until they have been maintained on therapeutic anticoagulation for a minimum of 3 weeks

23
Q

Afib: rate control agents

A

beta-blockers
dronedarone: second-line in patients following cardioversion
amiodarone: particularly if coexisting heart failure

24
Q

Afib: indication for catheter ablation

A

Patients with AF who have not responded to or wish to avoid, antiarrhythmic medication

25
Q

Catheter ablation: technical aspects

A

Objective: ablate the faulty electrical pathways that are resulting in atrial fibrillation. This is typically due to aberrant electrical activity between the pulmonary veins and left atrium

percutaneously, typically via femoral vein

both radiofrequency (uses heat generated from medium frequency alternating current) and cryotherapy can be used to ablate the tissue

25
Q

Catheter ablation: technical aspects

A

Objective: ablate the faulty electrical pathways that are resulting in atrial fibrillation. This is typically due to aberrant electrical activity between the pulmonary veins and left atrium

percutaneously, typically via femoral vein

26
Q

Catheter ablation: anticoagulation

A
  • 4 weeks before and during the procedure
  • patients still require anticoagulation as per their CHA2DS2-VASc score
    if score = 0: 2 months anticoagulation recommended
    if score > 1: longterm anticoagulation recommended
27
Q

Catheter ablation: COMPLICATIONS

A

cardiac tamponade
stroke
pulmonary vein stenosis

28
Q

Catheter ablation: success rate

A

around 50% –> early recurrence (within 3 months) of AF that often resolves spontaneously

longer term, after 3 years, around 55% of patients who’ve had a single procedure remain in sinus rhythm.

multiple procedures –> around 80% are in sinus rhythm

29
Q

Afib: post-stroke

A
  • following a TIA, anticoagulation for AF should start immediately (once imaging excludes haemorrhage)
  • in acute stroke patients, in the absence of haemorrhage, anticoagulation therapy should be commenced after 2 weeks
30
Q

Afib: Electrical cardioversion

A

Synchronised to R wave

31
Q

Afib: pharmacological cardioversion

A

<48hrs
Amiodarone or flecainide

32
Q

Cardioversion: anticoagulation

A

AF for more than 48 hours then anticoagulation should be given for at least 3 weeks prior to cardioversion.

Following electrical cardioversion if AF is confirmed as being less than 48 hours duration then further anticoagulation is unnecessary

33
Q

AVNRT

A

Small circuit around AV nodal tissue
- Re-entrant within AV node
- Fast and regular
- ECG: regular narrow complex tachycardia

34
Q

AVRT

A
  • Pre-excitation: in V1, initial slurring of QRS (delta wave) with short PR
  • Accessory pathway that allows electrical activation from atria to the ventricle (in addition to usual conduction down AV node)

Orthodromic AVRT -> ventricle activated down his-purk, circuit completed by going up into atria by bundle of Kent

Antidromic AVRT: ventricles activated by the accessory pathway, hence R ventricle before left -> broad QRS tachycardia

35
Q

Wolf-Parkinson White (AVRT)
- ECG
- Types
- Associations
- Management

A

congenital accessory conducting pathway between the atria and ventricles leading to a atrioventricular re-entry tachycardia (AVRT)

ECG
- short PR interval
- wide QRS complexes with a slurred upstroke - ‘delta wave’
Axis deviation
- left axis deviation if right-sided accessory pathway (Most common)
- right axis deviation if left-sided accessory pathway

Types
type A (left-sided pathway): dominant R wave in V1
type B (right-sided pathway): no dominant R wave in V1 (most common)

Associations
HOCM
mitral valve prolapse
Ebstein’s anomaly
thyrotoxicosis
secundum ASD

Management
definitive treatment: radiofrequency ablation of the accessory pathway
medical therapy: sotalol***, amiodarone, flecainide

***sotalol should be avoided if there is coexistent atrial fibrillation as prolonging the refractory period at the AV node may increase the rate of transmission through the accessory pathway, increasing the ventricular rate and potentially deteriorating into ventricular fibrillation

36
Q

Bradycardia: life-threatening signs

A

Same as tachycardia
- Shock
- Myocardial ischaemia
- Syncope
- Heart failure

37
Q

Bradycardia: life-threatening signs present

A

Atropine 500mcg

38
Q

Bradycardia: life-threatening signs not present

A

Risk of asystole?
* Recent asystole
* Mobitz II AV block
* Complete heart block with broad QRS
* Ventricular pause > 3 s

39
Q

Bradycardia: life-threatening signs not present + no risk of asystole

A

Observe

40
Q

Bradycardia: (life-threatening signs not present AND risk of asystole) OR Unsatisfactory response to Atropine

A

Interim measures:
* Atropine 500 mcg IV repeat to maximum of 3 mg
* Isoprenaline 5 mcg min-1 IV
* Adrenaline 2–10 mcg min-1 IV
* Alternative drugs*
or
Transcutaneous pacing

41
Q

If interim measures do not work

A

Seek expert help –> arrange transvenous pacing

42
Q

What is the MoA of atropine?

A

Blocks parasympathetic innervation

43
Q

Cautions and contra-indications to the use of Adenosine

A

CIs
- central line access or
- If already on dipyridamole or carbamazepine.
- Asthma (use verapamil instead)

Adenosine may be used in patients with heart transplants for rapid reversion to sinus rhythm and to aid the diagnoses of broad/narrow complex supraventricular tachycardias. It is important to note that patients with heart transplants are very sensitive to the effects of adenosine.

44
Q

List complications of SVT

A

Syncope
Deep vein thrombosis
Embolism
Cardiac tamponade
Congestive cardiac failure
Myocardial infarction
Death

45
Q

What are the 3 broad categories of device therapy

A
  1. For Bradycardia
    o Pacemaker – ensures HR never drops below certain value
  2. Susceptible to VT/VF (previous event or yet to have but have high risk)
    o Implantable Cardioverter Defibrillator (ICD) – shocks heart if it finds VT/VF
  3. Cardiac resynchronisation
    o BiVentricular (BiV) /Cardiac Resynchronisation Therapy (CRT) devices – placed to pace heart at all times in specific manner so that R and L ventricles contract simultaneously
46
Q

List causes of bradycardia

A

Can be normal in athletic individuals
Electrolyte disturbances
Hypothyrodism
Myocardial Infarction
Sepsis
Drugs e.g beta blockers
Increased intracranial pressure
Heart block

CARDIOVASCULAR (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions